Shots:
Q32 Bio has sold ADX-097, a P-II complement inhibitor, to Akebia Therapeutics
As per the deal, Akebia will acquire ADX-097 from Q32 Bio for ~$592M, incl. $12M in upfront & near-term milestones ($7M at signing, $3M after 6mos., $2M payable upon the earlier of a milestone or end-2026), plus development, regulatory & commercial milestones &…
